OralID’s fluorescence technology uses a blue light that allows a clinician to identify oral cancer, pre-cancer and other abnormal lesions at an earlier stage, thus saving lives.
OralID is the first oral screening light that combines proven fluorescence technology with a lack of per-patient disposables in a device that costs half as much as compared to others.
Team Training Included
We believe that every clinician deserves proper product training with every purchase. This ensures that the product is implemented properly and efficiently so it's utilized on every patient.
Easy to Use
Wearing the glasses provided and pressing a button means a clinician can distinguish between healthy and abnormal cells because the latter will appear dark due to a lack of fluorescence.
Due to its unique design, OralID is the only oral cancer screening device that allows you to screen your patients with no per-patient disposables.
Lack of per-patient cost allows the clinician to set their screening fees lower, enabling more patients to accept the exam. This, coupled with proper Team Training will create an additional revenue opportunity.
No Rinses. No Dyes. No More Excuses.
Forward Science Technologies sees the need to give back and serve those less fortunate. In efforts to provide dentists with technology that can save lives, Forward Science Technologies announces its program to donate an OralID to a non-profit 501(c)3 organization that serves underprivileged populations. For every 500 Likes on the OralID Facebook Page, an OralID oral cancer-screening device will be donated. The recipients will be announced on Facebook along with a link to their cause. "We believe that profits are great, but saving lives is better. The clinicians who serve underprivileged populations usually do not have the latest in screening technology. As these communities tend to have the highest risk factors for oral cancer and other oral diseases, we are striving to place this technology in the hands of clinicians who so selflessly give their free time to serve others" said Robert Whitman CEO.